NeonMind to Webcast Live at Life Sciences Investor Forum on June 24th
NeonMind to Webcast Live at Life Sciences Investor Forum on June 24th
Vancouver, B.C. – June 22, 2021 /GLOBE NEWSWIRE/ ‐‐ NeonMind Biosciences Inc. (CSE:
NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug
development and wellness company focused on the potential therapeutic uses of psilocybin for
treating obesity and weight management conditions, is pleased to announce that Robert
Tessarolo, President and Chief Executive Officer, will present live at
LifeSciencesInvestorForum.com on June 24th.
DATE: Thursday, June 24th
TIME: 3:00 PM ET
LINK: https://bit.ly/3c7Ertp
This will be a live, interactive online event where investors are invited to ask the company
questions in real‐time. If attendees are not able to join the event live on the day of the
conference, an archived webcast will also be made available after the event.
It is recommended that investors pre‐register and run the online system check to expedite
participation and receive event updates.
Learn more about the event at www.lifesciencesinvestorforum.com.
Recent Company Highlights
● Established international and US patent applications covering the spectrum of weight
management conditions
● Pre‐clinical study completed demonstrating weight sparing signal for low and high dose‐
psilocybin regime ‐ 4Q20
● Canadian eCommerce launch of four functional mushroom coffee blends for consumer
division – 4Q20
● Filed four (4) NHP applications with Health Canada to support the launch of consumer
products division ‐ 1Q21
● US $4.6M raised in January 2021 IPO – 1Q21
● Established Medical Services Division to launch NeonMind‐branded specialty mental
health clinics ‐ 2Q21
About NeonMind Biosciences Inc.
NeonMind is engaged in preclinical research to develop potential clinical treatments and
wellness products to address obesity and weight management conditions and to promote
health and wellness. The Company operates three divisions: (i) a pharmaceutical division
engaged in drug development of psychedelic compounds with two lead psilocybin‐based drug
candidates targeting obesity; (ii) a medical services division focused on launching specialty
mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy
settings; and (iii) a consumer products division that currently sells mushroom‐infused products
to promote health and wellness.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development
programs targeting obesity. NeonMind’s first drug candidate employs psilocybin as an agonist
to the serotonin receptor 5‐ HT2A, which is involved in the hallucinogenic effect of
psychedelics. The Company’s second drug candidate employs low‐dose psilocybin as an agonist
to the 5‐HT2C receptor, which controls appetite.
NeonMind established a medical services division with the goal of launching NeonMind‐
branded specialty mental health clinics in Canada that incorporate evidence‐backed innovative
treatments to address a variety of mental health needs.
NeonMind’s consumer division currently sells NeonMind‐branded coffee products in Canada
through NeonMind’s direct to consumer e‐commerce platform, and it has plans to launch
dietary supplements in the United States this quarter.
For more information on NeonMind, go to www.NeonMindBiosciences.com.
About Life Sciences Investor Forum
Life Sciences Investor Forum is the leading proprietary investor conference series that provides
an interactive forum for Life Sciences companies to meet with and present directly to investors.
A real‐time solution for investor engagement, Life Sciences Investor Forum is powered by
Intrado Digital Media and specifically designed for more efficient investor access. Replicating
the look and feel of on‐site investor conferences, Life Sciences Investor Forum combines
leading‐edge conferencing and investor communications capabilities with a comprehensive
global investor audience network.
CONTACTS:
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
Tel: 416‐750‐3101
Investor Relations:
Edge Communications
Tel: 1‐866‐318‐6874
KCSA Strategic Communications
Scott Eckstein/Tim Regan
Tel: 212‐896‐1210
Renmark Financial Communications Inc.
Melanie Barbeau
Tel: 416‐644‐2020 or 212‐812‐7680
Media Inquiries:
KCSA Strategic Communications
Annie Graf
Tel: 786‐390‐2644
Life Sciences Investor Forum
John M. Viglotti
SVP Corporate Services, Investor Access
(212) 220‐2221
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of
this news release.
Cautionary Statement Regarding Forward‐Looking Statements
Certain statements contained in this press release constitute forward‐looking information. These
statements relate to future events or NeonMind’s future performance. The use of any of the
words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and
statements relating to matters that are not historical facts are intended to identify forward‐
looking information and are based on NeonMind’s current belief or assumptions as to the
outcome and timing of such future events. Actual future results may differ materially. In
particular, NeonMind’s drug development plans, its ability to retain key personnel, and its
expectation as to the development of its intellectual property and other steps in its preclinical
and clinical drug development constitute forward‐looking information. Actual results and
developments may differ materially from those contemplated by forward‐looking information.
Readers are cautioned not to place undue reliance on forward‐looking information. The
statements made in this press release are made as of the date hereof. NeonMind disclaims any
intention or obligation to publicly update or revise any forward‐looking information, whether as
a result of new information, future events or otherwise, except as may be expressly required by
applicable securities laws.